Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Farah Mazahreh

Researcher

Also affiliated: Palmetto Hematology Oncology (2023); Arkansas Department of Agriculture (2022–2025); Indiana University School of Medicine (2023); Indiana University (2023)

Faculty Researcher

3 h-index 20 pubs 157 cited

  • COVID-19
  • Humans
  • Multiple Myeloma
  • Neutropenia
  • Antibodies, Bispecific
  • Neoplasms, Plasma Cell
  • Oncologists
  • Physicians
  • Career Choice
  • Surveys and Questionnaires

Biography and Research Information

OverviewAI-generated summary

Farah Mazahreh's research focuses on oncology, with recent work investigating the risk of infections associated with bispecific antibodies in multiple myeloma. This includes a pooled analysis examining this risk, with publications in both 2022 and 2023. Mazahreh has also explored other areas within oncology, including tumor response to immune-oncology therapy and the underlying molecular mechanisms of cancer therapy, with abstracts presented on synthetic lethality screens for cancer therapy and pancreas cancer. Beyond direct cancer research, Mazahreh has examined career choices for oncologists, specifically focusing on visa constraints. Additionally, the researcher has contributed to medical case studies, including an instance of inappropriate NSAID use in a human and venous thromboembolism while on anticoagulation.

Metrics

  • h-index: 3
  • Publications: 20
  • Citations: 157

Selected Publications

  • Abstract 3051: Enhancing matchmaking in targeted therapy (TT) for cancer (ca): Beyond the ‘arranged’ criteria (2026)
    Cancer Research DOI OpenAlex
  • Abstract 6288: Rational pairing of tumors with off-patent targeted therapies (TT): Next3 generation sequencing with global applications for the unprivileged patients. (2026)
    Cancer Research DOI OpenAlex
  • Abstract 5582: Interrogating the K-ras/p53 transcriptional readout for synthetic lethality applications (2025)
    Cancer Research DOI OpenAlex
  • Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing (2025)
    Cureus DOI OpenAlex
  • Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis (2025)
    Cureus 2 citations DOI OpenAlex
  • Abstract 3856: Nodal metastasis as an immune indicator in cancer (ca) therapy (2024)
    Cancer Research DOI OpenAlex
  • Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications (2024)
    Cancer Research DOI OpenAlex
  • Abstract 1567: Honing in on the metastasis machinery (2024)
    Cancer Research DOI OpenAlex
  • Visa Constraints and Career Choices for Oncologists (2023)
    Journal of the National Comprehensive Cancer Network 3 citations DOI OpenAlex
  • Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis (2023)
    Blood Advances 130 citations DOI OpenAlex
  • Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis (2022)
    Blood 16 citations DOI OpenAlex
  • “Ain’t She a Bute?”: The Importance of Proper History Taking in a Case of Inappropriate Use of Horse NSAID in a Human (2021)
    Clinics and Practice 3 citations DOI OpenAlex
  • Venous Thromboembolism While on Anticoagulation With Apixaban (2021)
    Cureus 2 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

26 Collaborators 3 Institutions 1 Country

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics